Quality of life among prostate cancer patients: A prospective longitudinal population-based study

Radiotherapy and Oncology

Volumn 108, Issue 2, 2013, Pages 299-305

  Schaake, Wouter ^a,b   De Groot, Martijn ^b   Krijnen, Wim P ^b,c   Langendijk, Johannes A ^a   Van Den Bergh, Alfons C M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HANZE UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Population based; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN;

ADULT; AGED; ARTICLE; ASTHMA; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; SOCIAL INTERACTION; TREATMENT DURATION; TREATMENT OUTCOME;

POPULATION-BASED; PROSTATE CANCER; QUALITY OF LIFE; RADIOTHERAPY;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REFERENCE VALUES; SICKNESS IMPACT PROFILE; TIME FACTORS;

EID: 84885376125     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.06.039     Document Type: Article

References (34)

1. D.E. Spratt, X. Pei, and J. Yamada Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 85 2013 686 692
2. A. Al-Mamgani, W.D. Heemsbergen, and P.C. Levendag Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial Radiother Oncol 96 2010 13 18
3. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129
4. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
5. S.H. van Oostrom, H.S.J. Picavet, and B.M. van Gelder Multimorbidity and comorbidity in the Dutch population-data from general practices BMC Public Health 12 2012 715
6. I. Lips, H. Dehnad, and A.B. Kruger Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study Int J Radiat Oncol Biol Phys 69 2007 656 661
7. M. Ferrer, J.F. Suárez, and F. Guedea Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 421 432
8. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Eng J Med 358 2008 1250 1261
9. L.V. van de Poll-Franse, F. Mols, and C.M. Gundy Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population Eur J Cancer 47 2011 667 675
10. P.M. Fayers Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30 Eur J Cancer 37 2001 1331 1334
11. Bolla M, de Reijke T. Long term adjuvant hormonal treatment with LHRH analogue versus no further treatment in locally advanced prostatic carcinoma treated by external irradiation and six months combined androgen blockage - a phase III study. EORTC Trial 22961. A joint trial of the EORTC Radiotherapy and EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC DATA CENTER. 1997.
12. Bolla M. EORTC Radiotherapy Cooperative Group, three dimensional conformal radiotherapy alone vs three dimensional conformal therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A Phase III Randomized Study. EORTC PROTOCOL 22991. 2000.
13. N. Aaronson, S. Ahmedzai, B. Bergman, and M. Bullinger The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
14. K. Cocks, M.T. King, and G. Velikova Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30 Eur J Cancer 48 2012 1713 1721
15. K. Cocks, M.T. King, and G. Velikova Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30 J Clin Oncol 29 2011 89 96
16. F. Mols, L.V. van de Poll-Franse, and A.J. Vingerhoets Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study Cancer 107 2006 2186 2196
17. A.L. Potosky, L.C. Harlan, and J.L. Stanford Prostate cancer practice patterns and quality of life J Natl Cancer Inst 91 1999 1719 1724
18. M.S. Litwin, and K.A. McGuigan Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer J Clin Oncol 17 1999 2882 2888
19. Y. Pardo, F. Guedea, and F. Aguiló Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment J Clin Oncol 28 31 2010 4687 4696
20. P.J. Hoskin, A.M. Rojas, and P.J. Ostler Quality of life after radical radiotherapy for prostate cancer: a longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dos rate brachytherapy Clin Oncol 25 2013 321 327
21. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Eng J Med 360 2009 2516 2527
22. J.Y. Bruce, J.M. Lang, and D.G. McNeel Current controversies in the management of biochemical failure in prostate cancer Clin Adv Hematol Oncol 10 2012 716 722
23. R.D. Crosby, R.L. Kolotkin, and G.R. Williams Defining clinically meaningful change in health-related quality of life J Clin Epidemiol 56 2003 395 407
24. S.D. Fosså, S.L. Hess, and A.A. Dahl Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis Acta Oncol 46 2007 452 461
25. M.L.G. Janssen-Heijnen, S. Houterman, and V.E.P.P. Lemmens Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach Critic Rev Oncol/Hematol 55 2005 231 240
26. S.D. Ramsey, S.B. Zeliadt, and I.J. Hall On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer J Urol 177 2007 1992 1999
27. L.V. van de Poll-Franse, L. Kwan, and R.E. Reiter The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study J Urol 179 2008 1362 1367
28. L.V. van de Poll-Franse, N. Sadetsky, and L. Kwan Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE Qual Life Res 17 2008 845 855
29. C.E. Schwartz, and M.A.G. Sprangers Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research Soc Sci Med 48 1999 1531 1548
30. D. Cell, E.A. Hahn, and K. Dineen Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 11 2002 207 221
31. S.A. Mangar, M.R. Sydes, and H.L. Tucker Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397) Radiother Oncol 80 2006 355 362
32. L. Incrocci Sexual function after external-beam radiotherapy for prostate cancer: what do we know? Critic Rev Oncol/Hematol 57 2006 165 173
33. M. Pinkawa, M.D. Piroth, and B. Asadpour Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis Strahlenther Onkol 185 2009 101 108
34. D. Osoba, G. Rodrigues, and J. Myles Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144